Eli Lilly and Company, a pharmaceutical giant with a market cap of nearly $952.3 billion, has been performing well in the market. Despite trading 6.7% below its January high, LLY stock has appreciated 21.2% over the past 52 weeks. The company’s Q4 fiscal 2025 results exceeded expectations, with revenue increasing 42.6% year over year to $19.29 billion. Eli Lilly’s management is optimistic about the future, forecasting revenue between $80 billion to $83 billion for fiscal 2026. Analysts have given the stock a “Strong Buy” rating, with an average price target of $1,233.65.

Read more at Barchart.: Is Eli Lilly Stock Underperforming the S&P 500?